| __timestamp | Halozyme Therapeutics, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 9136000 |
| Thursday, January 1, 2015 | 29245000 | 5807000 |
| Friday, January 1, 2016 | 33206000 | 5571000 |
| Sunday, January 1, 2017 | 31152000 | 5366000 |
| Monday, January 1, 2018 | 10136000 | 6337000 |
| Tuesday, January 1, 2019 | 45546000 | 11347000 |
| Wednesday, January 1, 2020 | 43367000 | 30419000 |
| Friday, January 1, 2021 | 81413000 | 62176000 |
| Saturday, January 1, 2022 | 139304000 | 52827000 |
| Sunday, January 1, 2023 | 192361000 | 35049000 |
| Monday, January 1, 2024 | 159417000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, cost management is crucial for success. This analysis compares the cost of revenue for Halozyme Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Halozyme's cost of revenue surged by approximately 747%, peaking in 2023. In contrast, Ligand's costs increased by about 283%, with a notable spike in 2021.
This divergence highlights Halozyme's aggressive growth strategy, while Ligand's steadier approach reflects a focus on cost efficiency. Understanding these trends offers valuable insights into each company's operational strategies and market positioning.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses